Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2008, for Zeta Acquisition Corp. II (not Whitehawk Therapeutics, Inc., as indicated in the metadata). The registrant is a Delaware corporation classified as a "blank check" company and a "shell company" in the development stage. Its sole purpose is to investigate and acquire a target business to achieve long-term growth. The company has no specific business plan or operations other than seeking a business combination.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Cumulative (Inception to Sep 30, 2008) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(4,188) | $(24,515) | $(39,492) |
| Cash and Cash Equivalents | $9,284 | $9,284 | $9,284 |
| Total Assets | $12,284 | $12,284 | $12,284 |
| Total Liabilities | $1,776 | $1,776 | $1,776 |
| Stockholders' Equity | $10,508 | $10,508 | $10,508 |
| Net Cash Used in Operating Activities | $(2,912) | $(29,989) | $(40,716) |
| Net Cash Provided by Financing Activities | $0 | $0 | $50,000 |
Debt and Liquidity: The company has no long-term debt. A $10,000 promissory note to a stockholder was issued and fully repaid from stock proceeds. Current liabilities consist solely of accounts payable and accrued expenses ($1,776). The company has no revenue and relies entirely on capital investment or loans from related parties to fund operations.
Material Changes vs. Prior Period
- Cash Position: Cash and cash equivalents decreased from $39,273 as of December 31, 2007, to $9,284 as of September 30, 2008, a reduction of approximately 76%.
- Liabilities: Total liabilities decreased from $4,250 to $1,776, primarily due to the repayment of the stockholder note and reduction in accrued expenses.
- Accumulated Deficit: The accumulated deficit during the development stage increased from $(14,977) to $(39,492) due to ongoing operational costs.
- Prepaid Expenses: The company recorded $3,000 in prepaid expenses as of September 30, 2008, compared to none at the end of 2007.
Outlook, Risks, and Management Commentary
Management Commentary: Management states that the company has not identified any business combination and cannot ascertain capital requirements for a transaction. The company anticipates incurring costs related to filing Exchange Act reports and investigating potential acquisitions over the next 12 months. It expects to meet these costs through treasury funds, fee deferrals, or additional loans/investments from stockholders and management.
Risks and Contingencies:
- Going Concern: The financial statements are presented on a going concern basis, which raises substantial doubt about the company's ability to continue operations without additional financing. The company has no assurance it can satisfy cash requirements for the next 12 months.
- Blank Check Status: As a "blank check" company, it has no specific business plan. It may acquire financially unstable or early-stage companies, subjecting investors to significant risks.
- Related Party Dependence: The company is dependent on related parties for funding and utilizes office space and equipment from an officer/director at no cost.
- Income Taxes: The company has gross deferred tax assets of approximately $5,900, but a full valuation allowance has been recorded due to uncertainty regarding future realization.
Investor Verification Checklist
- Company Identity: Verify that the filing is for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc.
- Liquidity Runway: Confirm the sufficiency of the remaining $9,284 cash balance to cover filing fees and operational costs for the next 12 months.
- Financing Sources: Investigate the availability of additional capital from the specific related parties mentioned as funding sources.
- Target Search Status: Review subsequent filings to determine if a target business combination has been identified or if the company remains in the development stage.
- Related Party Transactions: Monitor for new loans or equity issuances to related parties that may dilute existing shareholders or increase liabilities.